直接面向消费者的广告与前列腺癌超低分次放疗获益高估相关
该研究将400名40-80岁男性随机分入四组:去标识CyberKnife广告、带免责声明的广告、科学信息及对照,评估对超低分次放疗效果与安全性的印象。结果显示,观看广告者更倾向于选择CyberKnife并高估其疗效,免责声明仅减轻对副作用的正面印象,未纠正对疗效的高估。
要点
- 观看CyberKnife广告的男性更可能选择该治疗并高估其疗效。
- 免责声明可降低对副作用的正面印象,但不能纠正对疗效的高估。
- 科学信息可减少对CyberKnife在阳痿和排尿功能障碍方面优势的认同。
核心结论
- 直接面向消费者的医疗广告可能误导公众,使非专业人士对前列腺癌超低分次放疗的有效性和安全性产生不准确印象。
研究设计与样本
- 随机对照研究,纳入400名40-80岁男性,随机分入四组:去标识CyberKnife广告、带免责声明的广告、科学信息及对照。
主要发现
- 与对照组相比,观看任何三种干预材料的受试者更倾向于选择CyberKnife而非其他治疗(p < 0.01),广告组增加更明显。
- 观看科学信息的受访者更不认同CyberKnife在阳痿和排尿功能障碍方面具有优势。
- 免责声明降低了对CyberKnife副作用的正面印象,但未降低对疗效的正面印象。
- 广告组和带免责声明广告组的受访者均更可能认为CyberKnife更优。
临床怎么用
- 临床医生应警惕患者受直接面向消费者广告影响而高估超低分次放疗的获益,并主动提供科学信息以纠正误解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for stereotactic body radiation therapy. We hypothesized that those viewing an advertisement for CK versus factual information would have inaccurate impressions of effectiveness and safety. METHODS: 400 men aged 40-80 were randomly assigned to one of four arms: a de-identified CK advertisement, the same advertisement with disclaimers, scientific information obtained from review of contemporary peer-reviewed literature, and a control. Subjects answered questions regarding risks/benefits of CK and likelihood of pursuing CK versus other treatments. Regression analysis was performed to determine factors associated with CK preference. RESULTS: 400 men were included. Compared to controls, those who viewed any of the three interventions were more likely to pursue CK over other treatments (p < 0.01), with a greater increase in the advertisement groups. Respondents who viewed scientific information were less likely to agree CK is superior regarding impotence and urinary dysfunction. Disclaimers decreased positive impressions of CK's side effects, but not effectiveness. Both advertisement and advertisement with disclaimer respondents were more likely to consider CK superior. CONCLUSIONS: DTC medical advertisements can be misleading and impact laypersons' impressions. In this case, viewing an advertisement created inaccurate impressions regarding effectiveness and safety of UHF for prostate cancer.
引用
- Caputo JM, Lee HJ, Chiles B, et al. Exposure to direct-to-consumer advertising is associated with overestimation of benefits regarding ultrahypofractionated radiation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32367010. doi:10.1038/s41391-020-0234-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。